Niraparib Market
This report contains market size and forecasts of Niraparib in global, including the following ma ... Read More
1 Introduction to Research & Analysis Reports 1.1 Targeted Drug ALK Inhibitors for NSCLC Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1.5.2 Research Process 1.5.3 Base Year 1.5.4 Report Assumptions & Caveats 2 Global Targeted Drug ALK Inhibitors for NSCLC Overall Market Size 2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size: 2021 VS 2028 2.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size, Prospects & Forecasts: 2017-2028 2.3 Key Market Trends, Opportunity, Drivers and Restraints 2.3.1 Market Opportunities & Trends 2.3.2 Market Drivers 2.3.3 Market Restraints 3 Company Landscape 3.1 Top Targeted Drug ALK Inhibitors for NSCLC Players in Global Market 3.2 Top Global Targeted Drug ALK Inhibitors for NSCLC Companies Ranked by Revenue 3.3 Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Companies 3.4 Top 3 and Top 5 Targeted Drug ALK Inhibitors for NSCLC Companies in Global Market, by Revenue in 2021 3.5 Global Companies Targeted Drug ALK Inhibitors for NSCLC Product Type 3.6 Tier 1, Tier 2 and Tier 3 Targeted Drug ALK Inhibitors for NSCLC Players in Global Market 3.6.1 List of Global Tier 1 Targeted Drug ALK Inhibitors for NSCLC Companies 3.6.2 List of Global Tier 2 and Tier 3 Targeted Drug ALK Inhibitors for NSCLC Companies 4 Market Sights by Product 4.1 Overview 4.1.1 by Type - Global Targeted Drug ALK Inhibitors for NSCLC Market Size Markets, 2021 & 2028 4.1.2 Crizotinib 4.1.3 Ceritinib 4.1.4 Alectinib 4.1.5 Brigatinib 4.1.6 Lorlatinib 4.1.7 Other 4.2 By Type - Global Targeted Drug ALK Inhibitors for NSCLC Revenue & Forecasts 4.2.1 By Type - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2022 4.2.2 By Type - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2023-2028 4.2.3 By Type - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 5 Sights by Application 5.1 Overview 5.1.1 By Application - Global Targeted Drug ALK Inhibitors for NSCLC Market Size, 2021 & 2028 5.1.2 Squamous Cell Carcinoma of NSCLC 5.1.3 Adenocarcinoma of NSCLC 5.1.4 Large Cell Carcinoma of NSCLC 5.2 By Application - Global Targeted Drug ALK Inhibitors for NSCLC Revenue & Forecasts 5.2.1 By Application - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2022 5.2.2 By Application - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2023-2028 5.2.3 By Application - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 6 Sights by Region 6.1 By Region - Global Targeted Drug ALK Inhibitors for NSCLC Market Size, 2021 & 2028 6.2 By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue & Forecasts 6.2.1 By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2022 6.2.2 By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2023-2028 6.2.3 By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 6.3 North America 6.3.1 By Country - North America Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 6.3.2 US Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.3.3 Canada Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.3.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4 Europe 6.4.1 By Country - Europe Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 6.4.2 Germany Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.3 France Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.4 U.K. Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.5 Italy Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.6 Russia Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.7 Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.4.8 Benelux Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.5 Asia 6.5.1 By Region - Asia Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 6.5.2 China Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.5.3 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.5.4 South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.5.5 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.5.6 India Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.6 South America 6.6.1 By Country - South America Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 6.6.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.6.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.7 Middle East & Africa 6.7.1 By Country - Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 6.7.2 Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.7.3 Israel Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.7.4 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 6.7.5 UAE Targeted Drug ALK Inhibitors for NSCLC Market Size, 2017-2028 7 Players Profiles 7.1 Pfizer 7.1.1 Pfizer Corporate Summary 7.1.2 Pfizer Business Overview 7.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.1.4 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.1.5 Pfizer Key News 7.2 Novartis 7.2.1 Novartis Corporate Summary 7.2.2 Novartis Business Overview 7.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.2.4 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.2.5 Novartis Key News 7.3 Chugai Pharmaceutical (Hoffmann-La Roche group) 7.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Corporate Summary 7.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview 7.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Key News 7.4 ARIAD Pharmaceuticals (Takeda) 7.4.1 ARIAD Pharmaceuticals (Takeda) Corporate Summary 7.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview 7.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.4.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.4.5 ARIAD Pharmaceuticals (Takeda) Key News 7.5 Genvio Pharma Limited 7.5.1 Genvio Pharma Limited Corporate Summary 7.5.2 Genvio Pharma Limited Business Overview 7.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.5.4 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.5.5 Genvio Pharma Limited Key News 7.6 Beacon Pharma Limited 7.6.1 Beacon Pharma Limited Corporate Summary 7.6.2 Beacon Pharma Limited Business Overview 7.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.6.4 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.6.5 Beacon Pharma Limited Key News 7.7 Drug International Limted 7.7.1 Drug International Limted Corporate Summary 7.7.2 Drug International Limted Business Overview 7.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.7.4 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.7.5 Drug International Limted Key News 7.8 Incepta Pharmaceuticals 7.8.1 Incepta Pharmaceuticals Corporate Summary 7.8.2 Incepta Pharmaceuticals Business Overview 7.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Major Product Offerings 7.8.4 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue in Global Market (2017-2022) 7.8.5 Incepta Pharmaceuticals Key News 8 Conclusion 9 Appendix 9.1 Note 9.2 Examples of Clients 9.3 Disclaimer
List of Tables Table 1. Targeted Drug ALK Inhibitors for NSCLC Market Opportunities & Trends in Global Market Table 2. Targeted Drug ALK Inhibitors for NSCLC Market Drivers in Global Market Table 3. Targeted Drug ALK Inhibitors for NSCLC Market Restraints in Global Market Table 4. Key Players of Targeted Drug ALK Inhibitors for NSCLC in Global Market Table 5. Top Targeted Drug ALK Inhibitors for NSCLC Players in Global Market, Ranking by Revenue (2021) Table 6. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Companies, (US$, Mn), 2017-2022 Table 7. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Companies, 2017-2022 Table 8. Global Companies Targeted Drug ALK Inhibitors for NSCLC Product Type Table 9. List of Global Tier 1 Targeted Drug ALK Inhibitors for NSCLC Companies, Revenue (US$, Mn) in 2021 and Market Share Table 10. List of Global Tier 2 and Tier 3 Targeted Drug ALK Inhibitors for NSCLC Companies, Revenue (US$, Mn) in 2021 and Market Share Table 11. By Type – Global Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028 Table 12. By Type - Targeted Drug ALK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2017-2022 Table 13. By Type - Targeted Drug ALK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2023-2028 Table 14. By Application – Global Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028 Table 15. By Application - Targeted Drug ALK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2017-2022 Table 16. By Application - Targeted Drug ALK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2023-2028 Table 17. By Region – Global Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028 Table 18. By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), 2017-2022 Table 19. By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), 2023-2028 Table 20. By Country - North America Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022 Table 21. By Country - North America Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028 Table 22. By Country - Europe Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022 Table 23. By Country - Europe Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028 Table 24. By Region - Asia Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022 Table 25. By Region - Asia Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028 Table 26. By Country - South America Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022 Table 27. By Country - South America Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028 Table 28. By Country - Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022 Table 29. By Country - Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028 Table 30. Pfizer Corporate Summary Table 31. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 32. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 33. Novartis Corporate Summary Table 34. Novartis Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 35. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 36. Chugai Pharmaceutical (Hoffmann-La Roche group) Corporate Summary Table 37. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 38. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 39. ARIAD Pharmaceuticals (Takeda) Corporate Summary Table 40. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 41. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 42. Genvio Pharma Limited Corporate Summary Table 43. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 44. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 45. Beacon Pharma Limited Corporate Summary Table 46. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 47. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 48. Drug International Limted Corporate Summary Table 49. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 50. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) Table 51. Incepta Pharmaceuticals Corporate Summary Table 52. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Offerings Table 53. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022) List of Figures Figure 1. Targeted Drug ALK Inhibitors for NSCLC Segment by Type in 2021 Figure 2. Targeted Drug ALK Inhibitors for NSCLC Segment by Application in 2021 Figure 3. Global Targeted Drug ALK Inhibitors for NSCLC Market Overview: 2021 Figure 4. Key Caveats Figure 5. Global Targeted Drug ALK Inhibitors for NSCLC Market Size: 2021 VS 2028 (US$, Mn) Figure 6. Global Targeted Drug ALK Inhibitors for NSCLC Revenue, 2017-2028 (US$, Mn) Figure 7. The Top 3 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2021 Figure 8. By Type - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 9. By Application - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 10. By Region - Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 11. By Country - North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 12. US Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 13. Canada Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 14. Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 15. By Country - Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 16. Germany Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 17. France Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 18. U.K. Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 19. Italy Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 20. Russia Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 21. Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 22. Benelux Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 23. By Region - Asia Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 24. China Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 25. Japan Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 26. South Korea Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 27. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 28. India Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 29. By Country - South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 30. Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 31. Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 32. By Country - Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share, 2017-2028 Figure 33. Turkey Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 34. Israel Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 35. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 36. UAE Targeted Drug ALK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028 Figure 37. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 38. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 39. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 40. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 41. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 42. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 43. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 44. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
69
This report contains market size and forecasts of Niraparib in global, including the following ma ... Read More
This report contains market size and forecasts of Lorlatinib in global, including the following m ... Read More
This report contains market size and forecasts of Neratinib in global, including the following ma ... Read More
This report contains market size and forecasts of Osimertinib in global, including the following ... Read More